EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of aggressive non-Hodgkins lymphoma in elderly patients with thiotepa, Novantrone , vincristine, prednisone



Treatment of aggressive non-Hodgkins lymphoma in elderly patients with thiotepa, Novantrone , vincristine, prednisone



American Journal of Clinical Oncology 24(4): 360-362, August



The aging of the population and the increased incidence of non-Hodgkin's lymphoma will result in a large number of elderly patients with this disorder. Newer therapies will be required for this group of patients. This article reports a new therapy for elderly patients with diffuse aggressive non-Hodgkin's lymphoma. Patients were treated with TNOP (thiotepa 20 mg/m2, mitoxantrone (Novantrone) 10 mg/m2, vincristine (Oncovin) 1 mg/m2 all on day 1 and prednisone 60 mg/m2 on days 1 through 5 of a 21-day course. Twenty-six patients were enrolled on study. The patients' ages ranged from 66 years to 87 years, with a mean age of 75.5 years. Eleven patients had a partial response (42%) and 4 patients had a complete response (15%) for a total response of 57%. Eighty-one percent of patients survived 1 year and 54% survived for 2 years. The median survival was 26 months. Hematologic and nonhematologic toxicity was tolerable. We believe that TNOP is an excellent therapeutic option in this group of elderly patients, particularly in the palliative setting.

(PDF 0-2 workdays service: $29.90)

Accession: 035980889

Download citation: RISBibTeXText



Related references

Treatment of aggressive non-Hodgkin's lymphoma in elderly patients with thiotepa, Novantrone (mitoxantrone), vincristine, prednisone (TNOP). American Journal of Clinical Oncology 24(4): 360-362, 2001

Treatment of elderly patients with intermediate and high grade non-Hodgkins lymphoma A trial of thiotepa, novantrone , oncovin and prednisone. Blood 84(10 SUPPL 1): 164A, 1994

Vincristine - adriamycin continuous infusion in the treatment of elderly patients with aggressive non-Hodgkins lymphoma. Blood 92(10 SUPPL 1 PART 1-2): 238B, Nov 15, 1998

Treatment of early stages of Hodgkins disease with Novantrone, vincristine, prednisone, and radiotherapy. Seminars in Hematology 31(2 SUPPL 3): 36-43, 1994

A phase I study of pixantrone in combination with cyclophosphamide, vincristine and prednisone in patients with relapsed aggressive non-Hodgkins lymphoma. Blood 102(11): 642a, November 16, 2003

Treatment of aggressive non-Hodgkins lymphoma in the elderly with mitoxantrone, prednimustine and vincristine. Blood 82(10 SUPPL 1): 564A, 1993

CDOP , Vincristine, Prednisone as a front-line regimen for elderly patients with intermediate grade Non-Hodgkins Lymphoma. Blood 98(11 Part 2): 239b, November 16, 2001

A phase II trial of prednisone, oral etoposide, and novantrone (PEN) as initial treatment of non-Hodgkin's lymphoma in elderly patients. Leukemia & Lymphoma 18(1-2): 145-152, 1995

Liposomal doxorubicin in combination with cyclophosphamide , vincristine , and prednisone is active in newly diagnosed aggressive non-Hodgkins lymphoma. Blood 98(11 Part 1): 346a, November 16, 2001

Phase iii study of epirubicin vincristine and prednisone eop vs cyclophosphamide vincristine and prednisone cop in favorable non hodgkins lymphoma. 1987

Preliminary results of a phase II trial of pegylated liposomal doxorubicin , rituxan, cyclophosphamide, vincristine, and prednisone in aggressive B-cell non-Hodgkins lymphoma. Blood 102(11): 286b, November 16, 2003

Combination chemo therapy of hodgkins disease using thiotepa vincristine pro carbazine and prednisone. Proceedings of the American Association for Cancer Research 13: 71, 1972

Cyclophosphamide adriamycin vincristine and prednisone vs. methotrexate cyclophosphamide and vincristine for the treatment of non hodgkins lymphoma of unfavorable histopathology a randomized clinical trial. European Journal of Cancer and Clinical Oncology 21(2): 175-180, 1985

Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone). Annals of Hematology 87(9): 717-726, 2008

Prednimustine, mitoxantrone vs cyclophosphamide, vincristine, prednisone for the treatment of advanced low-grade non-Hodgkins lymphoma. Leukemia (Basingstoke) 10(5): 836-843, 1996